Clinical Trial Update: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2, single-arm study of volociximab monotherapy in platinum-resistant advanced epithelial ovarian cancer and primary peritoneal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Volociximab (volociximab)

Snippet

Sponsor: Facet Biotech | Conditions: Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Status: TERMINATED